ATB 352
Alternative Names: ATB-352Latest Information Update: 01 Aug 2024
At a glance
- Originator Antibe Therapeutics
- Class Analgesics; Anti-inflammatories; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules; Sulfides
- Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors; Prostaglandin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Postoperative pain
Most Recent Events
- 01 Aug 2024 ATB 352 is still in preclinical trials for Postoperative-pain in Canada (PO) (Antibe Therapeutics pipeline, August 2024)
- 01 Aug 2024 Discontinued - Preclinical for Postoperative pain in Canada (IV) (Antibe Therapeutics pipeline, August 2024)
- 28 May 2024 No recent reports of development identified for preclinical development in Postoperative-pain in Canada (IV, Liquid)